Virtual Posters

Big Data

PO-001 ARNTL2 is a hypoxia-responsive master regulator of PDAC malignancy. Alvaro Curiel-Garcia[1], Carlo H. Maurer[2], Pasquale Laise[3], Irina Sagalovskiy[4], John A. Chabot[4], Gulam A. Manji[4], Alina Iuga[5], Kristen Johnson[6], Andrea Califano[4], Kenneth P. Olive[4]. [1]Columbia University, New York, NY, [2]Technische Universität München, Munich, Germany, [3]Darwin Therapeutics, New York, NY, [4]Columbia University, New York, NY, [5]University of North Carolina, Chapel Hill, NC, [6]University of New Hampshire, Manchester, NH.

PO-002 Initial retrospective analysis of mechanisms of FOLFIRINOX resistance using clinical and molecular data from the Know Your Tumor (KYT) pancreatic ductal adenocarcinoma (PDAC) cohort. James M. Davison[1], Greg Mayhew[1], Kirk Beebe[1], Joel R. Eisner[1], Dennis Ladnier[2], Eric A. Collisson[3], Lynn M. Matrisian[2]. [1]GeneCentric Therapeutics, Inc, Durham, NC, [2]Pancreatic Cancer Action Network, Manhattan Beach, CA, [3]Division of Hematology and Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.

PO-003 Predictors for 30-day readmission in patients with pancreatic cancer who had DNR code status. Jasmeet Kaur[1], Tanveer Mir[2], Paramveer Singh[3], Judie Goodman[1]. [1]Saint Joseph Mercy Oakland Hospital, PONTIAC, MI, [2]Wayne State University, Detroit, MI, [3]Karmanos Cancer Center, Detroit, MI.

PO-004 Basal-like, Classical A, and Classical B subtypes of pancreatic cancer show distinct immuno-suppressive molecular profiles. Emily L. LaPlante[1], Dongliang Liu[1], Aleksandar Milosavljevic[1], Qizhi Yao[1]. [1]Baylor College of Medicine, Houston, TX.

PO-005 Proteome profiling of Pancreatic Ductal Adenocarcinoma (PDAC) primary tumors in Caucasian, African Americans and Latinx patients. Henry C. H. Law[1], Andrea N. Riner[2], Jose G. Trevino[3], Nicholas T. Woods[1]. [1]University of Nebraska Medical Center, Omaha, NE, [2]University of Florida, Gainesville, FL, [3]Virginia Commonwealth University, Richmond, VA.

Diagnostics, Early Detection, and Imaging

PO-006 CircRTN4 promotes pancreatic cancer progression through a novel circRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein. Chi Hin Wong[1], Ut Kei Lou[1], Frederic Khe-Cheong Fung[1], Joanna H. M. Tong[2], Ka-Fai To[2], Stephen Lam Chan[3], Yangchao Chen[4]. [1]School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China-Hong Kong, [2]Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China-Hong Kong, [3]Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China-Hong Kong, [4]School of Biomedical Sciences, Faculty of Medicine, and Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong, China-Hong Kong.

PO-007 Plasma-based detection of pancreatic cancer: A multiomics approach. Teng-Kuei Hsu[1], Tzu-Yu Liu[1], Billie Gould[1], Christine Decapite[2], Amer Zureikat[3], Alessandro Paniccia[3], Eric Ariazi[1], Marvin Bertin[1], Richard Bourgon[1], Kaitlyn Coil[1], Hayley Donnella[1], Adam Drake[1], Julie M. Granka[1], Preet Kaur[1], Maggie C. Louie[1], Shivani Mahajan[1], Amit Pasupathy[1], Ofer Shapira[1], Peter Ulz[1], Chun Yang[1], C. Jimmy Lin[1], Randall Brand[2]. [1]Freenome Holdings Inc., South San Francisco, CA, [2]Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, [3]Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.

PO-008 Diagnostic accuracy of blood-based multi-omic biomarkers for pancreatic adenocarcinoma: A systematic review and meta-analysis. Laura E. Kane[1], Gregory S. Mellotte[2], Eimear Mylod[1], Rebecca O'Brien[1], Fiona O'Connell[1], Khanh Nguyen[3], Croí E. Buckley[1], Jennifer Arlow[3], David Mockler[1], Aidan D. Meade[3], Barbara M. Ryan[2], Stephen G. Maher[1]. [1]Trinity College Dublin, Dublin, Ireland, [2]Tallaght University Hospital, Dublin, Ireland, [3]Technological University Dublin, Dublin, Ireland.

PO-009 Multi-omic profiling of patient pancreatic cyst fluid for the identification of a novel biomarker panel of patient cancer risk. Laura E. Kane[1], Gregory S. Mellotte[2], Simone Marcone[1], Barbara M. Ryan[2], Stephen G. Maher[1]. [1]Trinity College Dublin, Dublin, Ireland, [2]Tallaght University Hospital, Dublin, Ireland.

PO-010 Detection of early tissue changes on historical CT scans in the regions of the pancreas gland that subsequently develop adenocarcinoma using quantitative textural analysis and fat fraction analysis. Ronald L. Korn[1], Daniel D. Von Hoff[2], Andre Burkett[1], Dominic Zygadlo[1], Taylor Brodie[3], Kathleen Panak[1], Sweta Rajan[1], Derek Cridebring[2], Michael J. Demeure[3]. [1]Imaging Endpoints, Scottsdale, AZ, [2]Translational Genomics Research Institute, Phoenix, AZ, [3]Hoag Hospital, Newport Beach, CA.

PO-011 The spectrum of pathogenic germline variants in pancreatic cancer patients with multiple primary tumors. Valentyna Kryklyva[1], Lodewijk A.A. Brosens[2], Marjolijn J.L. Ligtenberg[1], Iris D. Nagtegaal[1]. [1]Radboud university medical center, Nijmegen, Netherlands, [2]University Medical Center Utrecht, Utrecht, Netherlands.

PO-012 The concept of artificial intelligence against pancreatic cancer. Subash Kumar[1]. [1]DMI Lochbridge, Elkridge, MD.

PO-013 Comparison of novel healthcare delivery models on the uptake of genetic education and testing in families with a history of pancreatic cancer: The GENetic Education, Risk Assessment and TEsting (GENERATE) Study. Nicolette J. Rodriguez[1], Constance S. Furniss[2], Matthew B. Yurgelun[3], Chinedu Ukaegbu[4], Pamela E. Constantinou[5], Alison N. Schwartz[4], Jill Stopfer[4], Meghan Underhill-Blazey[6], Barbara Kenner[7], Scott Nelson[8], Sydney Okumura[9], Sherman Law[9], Alicia Y. Zhou[9], Tara B. Coffin[10], Hajime Uno[2], Allyson Ocean[11], Florencia McAllister[5], Andrew M. Lowy[12], Scott M. Lippman[12], Alison P. Klein[13], Lisa Madlensky[12], Gloria M. Petersen[14], Judy E. Garber[1], Michael G. Goggins[13], Anirban Maitra[5], Sapna Syngal[3]. [1]Dana-Farber Cancer Institute / Brigham and Women's Hospital / Harvard

Medical School, Boston, MA, [2]Dana-Farber Cancer Institute / Harvard Medical School, Boston, MA, [3]Dana-Farber Cancer Institute / Brigham and Women's Hospital / Harvard Medical School, Boston, MA, [4]Dana-Farber Cancer Institute, Boston, MA, [5]Sheikh Ahmed Center for Pancreatic Cancer Research / University of Texas MD Anderson Cancer Center, Houston, TX, [6]University of Rochester, Rochester, NY, [7]Kenner Family Research Fund, New York, NY, [8]Pancreatic Cancer Action Network Volunteer, Manhattan Beach, CA, [9]Color Genomics, Burlingame, CA, [10]University of Washington, Seattle, WA, [11]Weill Cornell Medical Center, New York, NY, [12]Moores Cancer Center / UC San Diego, San Diego, CA, [13]Johns Hopkins University / Sol Goldman Pancreatic Cancer Research Center, Baltimore, MD, [14]Mayo Clinic, Rochester, MN.

PO-014 VISTA: VIsual Semantic Tissue Analysis for pancreatic disease quantification in murine cohorts. Luke Ternes[1], Ge Huang[1], Christian Lanciault[1], Guillaume Thibault[1], Rachelle Riggers[2], Joe Gray[2], John Muschler[1], Young Hwan Chang[1]. [1]Oregon Health and Science University, Portland, OR, [2]Oregon Health and Science Univeristy, Portland, OR.

Early Phase Clinical Trials

PO-015 A phase Ib/II trial of high dose ascorbic acid (AA) + paclitaxel protein bound (PP) + cisplatin (C) + gemcitabine (G) in patients (pts) with previously untreated metastatic pancreatic cancer (MPC). Gayle S. Jameson[1], Erkut H. Borazanci[1], Daniel D. Von Hoff[2], Joshua D. Rabinowitz[3], Michael S. Gordon[1], Sarah D. LeGrand[1], Courtney Snyder[1], Karen Ansaldo[1], Denise J. Roe[4], Haiyong Han[2]. [1]HonorHealth, Scottsdale, AZ, [2]Translational Genomics Research Institute (TGen), Phoenix, AZ, [3]Princeton University, Princeton, NJ, [4]University of Arizona Cancer Center, Tucson, AZ.

Immunotherapy

PO-016 Directed evolution generates novel oncolytic H-1 parvoviruses with improved therapeutic efficacy in virus-resistant pancreatic cancer cells. Pierre Garcin[1], Monireh Kazemimanesh[1], Hubert Lulka[1], Nelson Dusetti[2], Guillaume Labrousse[1], Emilie Benuzzi[1], Louis Buscail[3], Pierre Cordelier[1]. [1]Cancer Research Center of Toulouse, INSERM, Toulouse, France, [2]Cancer Research Center of Marseilles, INSERM, Marseilles, France, [3]Cancer Research Center of Toulouse, INSERM and Toulouse University Hospital, Toulouse, France.

PO-017 Application of oncolytic adenovirus to desmoplastic pancreatic cancer. Elora Hossain[1], Fumihiro Higashino[1]. [1]Hokkaido University, Sapporo, Japan.

PO-018 Inflaming advanced solid tumors including pancreatic cancer using LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic virus. Jessica Wenthe[1], Emma Eriksson[2], Linda Sandin[3], Tanja Lövgren[2], Justyna Leja Jarblad[3], Hanna Dahlstrand[4], Ulla Olsson-Strömberg[4], Aglaia Schiza[4], Anders Sundin[4], Sandra Irenaeus[4], Eric Rowinsky[5], Gustav Ullenhag[4], Angelica Loskog[6]. [1]Uppsala University, Uppsala, Sweden, [2]Uppsala university, Uppsala, Sweden, [3]Lokon Pharma AB, Uppsala, Sweden, [4]Uppsala University Hospital, Uppsala, Sweden, [5]Lokon Pharma AB, New York, NY, [6]Uppsala University & Lokon Pharma AB, Uppsala, Sweden.

PO-019 Reprogramming of naïve B cells in pancreatic cancer subverts humoral immunity. Bhalchandra Mirlekar[1], Yuliya Pylayeva-Gupta[1]. [1]Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.

PO-020 Heating up immune cold pancreatic adenocarcinoma with bioengineered immunotherapy remodels tumor microenvironment and prevents metastasis *in vivo.* Chanthirika Ragulan[1], Patrick Varun Lawrence[1], Hari PS[1], Krisha Desai[1], Jun Ishihara[2], Anguraj Sadanandam[1]. [1]The Institute of Cancer Research, Sutton, United Kingdom, [2]Imperial College London, London, United Kingdom.

Metabolism

PO-021 Targeting the mitochondrial pyruvate complex to alter metabolic programming in pancreatic cancer. Hassan A. Ali[1], Andrew Metcalfe[2], James T. Topham[2], Cassia S. Warren[2], Joanna M. Karasinska[2], David F. Schaeffer[2], Daniel J. Renouf[2]. [1]University of British Columbia, Vancouver, BC, Canada, [2]Pancreas Centre BC, Vancouver, BC, Canada.

PO-023 Impaired adipose anabolism drives fat wasting in pancreatic cancer cachexia. Katherine Pelz[1], Grace McCarthy[1], Heike Mendez[1], Samantha Z. Brown[1], Jonathan R. Brody[1], Aaron J. Grossberg[1]. [1]Oregon Health & Science University, Portland, OR.

PO-024 Targeting cellular metabolism with CPI-613 sensitizes pancreatic cancer cells to radiotherapy. William A. Hall[1], Husain Y. Khan[2], Mandana Kamgar[1], Susan Tsai[1], Kathleen Christians[1], Douglas B. Evans[1], Philip Philip[2], Callisia Clarke[1], Ben George[1], Beth Erickson[1], Asfar S. Azmi[2]. [1]Medical College of Wisconsin, Milwaukee, WI, [2]Karmanos Cancer Institute, Wayne State University, Detroit, MI.

PO-025 Investigating lipid homeostasis in pancreatic ductal adenocarcinoma under tumor-like stress. Xu Han, Michelle Burrows, Celeste Simon, Yanqing Jiang, Brian Keith. University of Pennsylvania, Philadelphia, PA.

PO-026 CircMYOF acts as a miR-4739 sponge to promote progression and facilitate glycolysis via VEGFA/PI3K/AKT pathway in pancreatic ductal adenocarcinoma. Dandan Zheng[1], Xianxian Huang[2], Juanfei Peng[1], Yanyan Zhuang[1], Yuanhua Li[3], Junchi Qu[1], Shineng Zhang[1], Fengting Huang[1]. [1]Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, [2]the Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China, [3]Tungwah Hospital of Sun Yat-sen University, Dongguan, China.

PO-027 Investigating unfolded protein responses in pancreatic ductal adenocarcinoma under lipid imbalance. Yanqing (Christine) Jiang, Xu Han, Michelle Burrows, Carson Poltorack, Celeste Simon, Brian Keith. University of Pennsylvania, Philadelphia, PA.

PO-028 PO-028 Pancreatic ductal adenocarcinoma is dependent on an unconventional pathway for polyamine synthesis. Min-Sik Lee[1,2,3], Insia Naqvi[1], Courtney Dennis[4], Lucas Dailey[4], Alireza Lorzadeh[5], Tamara Zaytouni[1], Ashley Adler[1,3], Daniel S. Hitchcock[4], Lin Lin[1], Unmesh Jadhav[5,6], Clary B. Clish[4], and Nada Y. Kalaany[1,2,3]. [1]Division of

Endocrinology, Boston Children's Hospital, Boston, MA, [2]Department of Pediatrics, Harvard Medical School, Boston, [3]Broad Institute of MIT and Harvard, Cambridge, MA, [4]Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, [5]Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, [6]Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.

PO-029 Pancreatic cancer-associated cachexia as a 3-stage systemic disease with changes in body composition, tissue-specific wasting across time and alterations in glucose metabolism. Blanca Majem[1], Insia Naqvi[1], Courtney Dennis[2], Lucas Dailey[2], Clary B. Clish[2], Nada Kalaany[1]. [1]Boston Children's Hospital, Harvard Medical School, Boston, MA, [2]Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA.

PO-031 Lysosome inhibition overcomes resistance to CDK4/6 inhibition in PDA. Dilru Silva, Conan Kinsey, Martin McMahon. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.

Microbiome

PO-033 Bacterial cytotoxin therapy limits tumor growth for pancreatic ductal adenocarcinoma. Amanda R. Decker[1], Tetsuhiro Harimoto[2], Steve A. Sastra[1], Tal Danino[2], Kenneth P. Olive[1]. [1]Columbia University Medical Center, New York, NY, [2]Columbia University, New York, NY.

Other

PO-034 CPSF3 inhibition halts pancreatic cancer cell proliferation by limiting core histone supplies. Abdulrahman A. Alahmari[1], Carla Schwarz[2], Emily Paterson[2], Swati Venkat[2], Arwen Tisdale[2], Michael E. Feigin[2]. [1]Roswell Park Comprehensive Cancer Center, Amherst, NY, [2]Roswell Park Comprehensive Cancer Center, Buffalo, NY..

PO-036 LP184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects. Diana Restifo[1], Aditya Kulkarni[2], Caleb Schimke[2], Joseph McDermott[2], Umesh Kathad[2], Kishor Bhatia[2], Panna Sharma[2], Igor Astsaturov[1]. [1]Fox Chase Cancer Center, Philadelphia, PA, [2]Lantern Pharma, Dallas, TX.

PO-037 Development of an RGD CRISPR-modified *Clostridium novyi* NT Spores as an Intravenous Oncotherapy. Kaitlin M. Dailey[1], Krysten Vance[2], Kyle McAndrews[3], Reed I. Jacobson[4], Jandro Delgado[4], Paige R. Johnson[5], Taylor M. Woolery[5], Megan Orr[6], Jiha Kim[7], Sanku Mallik[5], Kenneth W. Bayles[8], Michael A. Hollingsworth[2], Amanda E. Brooks[9]. [1]Eppley Institute for Cancer Research, University of Nebraska Medical Center, and Cell and Molecular Biology Program, Pharmaceutical Sciences Department, North Dakota State University, Omaha, NE, [2]Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, NE, [3]Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, Omaha,

NE, [4]Department of Biological Sciences, North Dakota State University, Fargo, ND, [5]Cell and Molecular Biology Program, Pharmaceutical Sciences Department, North Dakota State University, Fargo, ND, [6]Department of Statistics, North Dakota State University, Fargo, ND, [7]Cell and Molecular Biology Program, Pharmaceutical Sciences Department and Department of Biological Sciences, North Dakota State University, Fargo, ND, [8]Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, [9]Cell and Molecular Biology Program, Pharmaceutical Sciences Department, North Dakota State University, Fargo, ND and Department of Research and Scholarly Activity, Rocky Vista University, Ivins, UT, Fargo, ND.

PO-038 LAMC2: new player in stemness and tumor progression in pancreatic cancer. Donatella Delle Cave[1], Tea Teresa Iavazzo[1], Maria Mangini[2], Gennaro Andolfi[1], Teresa Pirozzi[1], Annalisa Di Domenico[1], Annachiara De Luca[2], Enza Lonardo[1]. [1]Institute of Genetics and Biophysics 'Adriano Buzzati-Traverso' (IGB), CNR, Naples, Italy, [2]Institute of Biochemistry and Cellular Biology, National Research Council of Italy, Naples, Italy.

PO-039 Antiproliferative activity of inhibitors of RAD51, singly and in combination with chemotherapy drugs, against pancreatic cancer cell lines. Peter Ferguson[1], Mark D. Vincent[1], Yousef Najajreh[2], Brian Shilton[3], Stephen Ritter[3], Rima Al-awar[4], Richard Marcellus[4], Mohammed Mohammed[4], Methvin Isaac[5], James Koropatnnick[4]. [1]London Health Sciences Centre, London, ON, Canada, [2]Al Quds University, Jerusalem, Palestinian Territory, [3]Western University, London, ON, Canada, [4]Ontario Institute for Cancer Research, Toronto, ON, Canada.

PO-040 Nischarin is expressed in pancreatic ductal adenocarcinoma and is a potential target for drug repurposing. Jelena Grahovac[1], Marijana Pavlovic[1], Marija Ostojic[1], Kristina Zivic[1], Daniel Galun[2], Tatjana Srdic-Rajic[1]. [1]Institute for Oncology and Radiology of Serbia, Belgrade, Serbia, [2]School of Medicine, University of Belgrade; First Surgical Clinic, Clinical Center of Serbia, Belgrade, Serbia.

PO-041 Systemic screening of gene delivery methods in pancreatic ductal adenocarcinoma cells. Dmytro Grygoryev[1], Taelor Ekstrom[1], Jason M. Link[2], Rosalie C. Sears[2], Jungsun Kim[1]. [1]Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Portland, OR, [2]Oregon Health & Science University, Portland, OR.

PO-043 Cytidine deaminase protects pancreatic cancer cells from replicative stress and drive response to DNA-targeting drugs. Audrey Lumeau[1], Nicolas Bery[1], Cyril Ribeyre[2], Samad Elkaoutari[3], Guillaume Labrousse[1], Miguel Madrid-Mencia[1], Vera Pancaldi[1], Marie-Jeanne Pillaire[4], Valérie Bergoglio[5], Nelson Dusseti[3], Jean-Sébastien Hoffmann[6], Louis Buscail[7], Malik Lutzmann[2], Pierre Cordelier[1]. [1]Cancer Research Center of Toulouse, Toulouse, France, [2]IGH Montpellier, Montpellier, France, [3]Cancer Research Center of Marseille, Marseille, France, [4]IPBS Toulouse, Toulouse, France, [5]CBI Toulouse, Toulouse, France, [6]IUCT Oncopole Toulouse, Toulouse, France, [7]CHU Rangeuil Toulouse, Toulouse, France.

PO-044 Mechanobiological analysis of human patient pancreatic cancer tissues and the effect of cellular transmembrane mucins on glycocalyx-actomyosin mechanics. Andrew Massey. National Institutes of Health, Bethesda, MD.

PO-045 Targeting HNF1A-dependent cell proliferation and stemness in PDAC using BET inhibitors. Bharani Muppavarapu, Ethan Abel, Melanie Mayberry. Roswell Park Comprehensive Cancer Center, Buffalo, NY.

PO-046 The effect of neoadjuvant therapy on immune profiling of pancreatic ductal adenocarcinoma: a prospective study of the PREOPANC-1 randomized controlled trial. Diba Latifi, Willem de Koning, Sai ping Lau, Frederiek Grevers, Coen van Dam, Casper H. J. van Eijck, Dana A. M. Mustafa. Erasmus University Medical Center, Rotterdam, Netherlands.

PO-047 Optimizing the efficacy of 5-FU as a chemotherapeutic agent in advanced pancreatic ductal adenocarcinoma (PDAC) using MIAPaCa-2 and PANC-1 cells. Nkafu Bechem Ndemazie[1], Andriana Inkoom[1], Xue Y. Zhu[1], Edward Agyare[1]. [1]Florida A&M University, Tallahassee, FL.

PO-048 A novel chromatin remodeling domain of keratin 17 regulates transcription and promotes tumor aggression in pancreatic cancer. Chun-Hao Pan[1], Robert Tseng[1], Simon J. Hogg[2], Gabriella Baraks[1], Cindy V. Leiton[1], Lucia Roa-Peña[1], Natalia Marchenko[1], Kenneth R. Shroyer[1], Luisa F. Escobar-Hoyos[3]. [1]Stony Brook University, Stony Brook, NY, [2]Memorial Sloan Kettering Cancer Center, New York, NY, [3]Yale University, New Haven, CT.

PO-049 Inhibiting MNK kinases promotes macrophage immunosuppressive phenotype to limit anti-tumor immunity. Thao ND Pham[1], Christina Spaulding[1], Mario A. Shields[1], Mahmoud G. Khalafalla[1], Daniel R. Principe[2], David J. Bentrem[1], Hidayatullah G. Munshi[1]. [1]Feinberg School of Medicine, Northwestern University, Chicago, IL, [2]Medical Scientist Training Program, College of Medicine, University of Illinois at Chicago, Chicago, IL.

PO-050 Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC). Vincent J. Picozzi[1], Anne-Marie Duliege[2], Anirban Maitra[3], Manuel Hidalgo[4], Andrew Eugene Hendifar[5], Gregory L. Beatty[6], Sudheer Doss Doss[2], Regina Deck[2], Lynn M. Matrisian[2], Julie Fleshman[2], Diane M. Simeone[7]. [1]Virginia Mason Hospital and Medical Center, Seattle, WA, [2]Pancreatic Cancer Action Network, Manhattan Beach, CA, [3]University of Texas MD Anderson Cancer Center, Houston, TX, [4]Weill Cornell Medicine, New York, NY, [5]Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, [6]University of Pennsylvania, Philadelphia, PA, [7]NYU Langone Health, New York, NY.

PO-051 PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma. Vincent J. Picozzi[1], Teresa Macarulla[2], Philip A. Philip[3], Carlos R. Becerra[4], Tomislav Dragovich[5]. [1]Virginia Mason Hospital and Medical Center, Seattle, WA, [2]Vall d'Hebrón University Hospital and Vall d'Hebrón Institute of Oncology, Barcelona, Spain, [3]Karmanos

Cancer Institute, Detroit, MI, [4]Baylor University Medical Center, Dallas, TX, [5]Banner MD Anderson Cancer Center, Gilbert, AZ.

PO-052 A pilot study of miRNA expression profile in surgically resected pancreatic ductal adenocarcinoma: Initial report from a bi-institutional cohort. Luca Pompella[1*], Michela Falco[2*], Carlo Caputo[2*], Anna Grimaldi[2], Giuseppe Tirino[1], Severo Campione[3], Francesca Sparano[1], Maria Lucia Iacovino[1], Chiara Carmen Miceli[1], Carlo Molino[4], Marco Montella[5], Renato Franco[5], Gennaro Galizia[6], Giovanni Conzo[7], Vincenzo Napolitano[7], Annamaria Auricchio[6], Francesca Cardella[6], Fortunato Ciardiello[1], Michele Caraglia[2], Angela Lombardi[2], Gabriella Misso[2*] and Ferdinando De Vita[1*]. [1]Department of Precision Medicine, Division of Medical Oncology, University of Campania "L. Vanvitelli", Aversa, Italy, [2]Department of Precision Medicine, Division of Molecular Pathology, University of Campania "Luigi Vanvitelli", Naples, Italy, [3]Department of Precision Medicine, Division of Medical Oncology, University of Campania "L. Vanvitelli", Naples, Italy, [4]Division of Surgical Pathology, AORN "Antonio Cardarelli", Naples, Italy, [5]Division of General Surgery 1, AORN "Antonio Cardarelli", Naples, Italy, [6]Division of Surgical Pathology, University of Campania "Luigi Vanvitelli", Naples, Italy, [7]Department of Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy, [8]Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy, [9]Department of Precision Medicine, Division of Molecular Pathology, University of Campania "L. Vanvitelli", Naples, Italy. * These authors contributed equally to this work.

PO-054 A phase II trial of the super-enhancer inhibitor Minnelide in advanced refractory adenosquamous carcinoma of the pancreas (ASCP). Nebojsa Skorupan[1], Mehwish I. Ahmad[1], Seth M. Steinberg[1], Jane B. Trepel[1], Derek Cridebring[2], Haiyong Han[2], Daniel D. Von Hoff[2], Christine Alewine[1]. [1]CCR, Bethesda, MD, [2]Translational Genomics Research Institute, Phoenix, AZ.

PO-055 Phase II clinical trial of subtype directed neoadjuvant therapy in patients with localized pancreatic cancer. Susan Tsai[1], Erkut Borazanci[2], Margaret Gulley[3], Naim Rashid[3], Jason Merker[3], Abdul H Khan[1], Phillip Chisholm[1], Bryan Hunt[1], Tamara Giorgadze[1], William Hall[1], Mandana Kamgar[1], Douglas B Evans[1], Jen Jen Yeh[3]. [1]Medical College of Wisconsin, Milwaukee, WI, [2]Honor Health Medical Group, Scottsdale, AZ, [3]University of North Carolina, Chapel Hill, NC.

PO-056 Insulin receptor signaling in pancreatic acinar cells contributes to pancreatic cancer development. Anni M.Y. Zhang, Jenny C.C. Yang, Twan J.J. de Winter, David F. Schaeffer, Janel L. Kopp, James D. Johnson. The University of British Columbia, Vancouver, BC, Canada.

PO-057 Targeting ErbB2 degradation via the ubiquitin–proteasome pathway to inhibit

the metastasis of pancreatic cancer. Bo Zhang, Fei Teng, Nengming Lin. Hangzhou First People's Hospital, Hangzhou, China.

Preclinical Models

PO-058 Anti-cancer activity of NTAX-44 (bioprocessed arsenic trioxide) on pancreatic cancer cell line. Yogesh Bendale[1], Padma Shastri[2], Radha Poojari[3], Nandinee Khot[2], Surendra Nagare[2], Avinash Kadam[2]. [1]Rasayu Cancer Clinic, Pune, India, [2]Rasayani Biologics Pvt. Ltd, Pune, India, [3]Innovation Centre, Tata Chemicals Ltd., Pune, India.

PO-059 Epithelial/mesenchymal identity dictates pancreatic cancer cell metastasis. Julienne L. Carstens[1], Sujuan Yang[1], Pedro Correa de Sampaio[1], Xiaofeng Zheng[1], Souptik Barua[2], Kathleen M. McAndrews[1], Arvind Rao[3], Jared K. Burks[1], Andrew D. Rhim[1], Raghu Kalluri[1]. [1]MD Anderson Cancer Center, Houston, TX, [2]Rice University, Houston, TX, [3]University of Michigan, Ann Arbor, MI.

PO-060 N-terminal RHAMM cooperates with dysfunctional p53 to accelerate the progression of pancreatic cancer. Anthony Lin[1], Jennifer Feng[1], Xiang Chen[1], Dunrui Wang[2], Megan Wong[1], George Zhang[1], Joseph Na[1], Tiantian Zhang[1], Zhengming Chen[1], Yao-Tseng Chen[1], Yi-Chieh Nancy Du[1]. [1]Weill Cornell Medicine, New York, NY, [2]National Institutes of Health, Bethesda, MD.

PO-061 Myc drives phenotypic heterogeneity, metastasis, and therapy resistance in pancreatic ductal adenocarcinoma. Isabel A. English[1], Patrick J. Worth[1], Amy T. Farrell[1], Brittany L. Allen-Petersen[2], Vidhi Shah[1], Courtney Betts[1], Xiaoyan Wang[1], Colin J Daniel[1], Mary C. Thoma[1], Lisa M. Coussens[1], Ellen M. Langer[1], Rosalie C. Sears[1]. [1]Oregon Health & Science University, Portland, OR, [2]Purdue University, West Lafayette, IN.

PO-062 EUS-guided biopsy of pancreatic mass lesions for the development of patient-derived organoids in Puerto Rico. Andrea S. Flores Pérez[1], Janet Mendez Vega[1], Ana M. Reyes Ramos[1], Carlos Micames[2], Madeline Torres-Lugo[1], Maribella Domenech[1]. [1]University of Puerto Rico - Mayagüez, Mayagüez, Puerto Rico, [2]Hospital Bella Vista, Mayagüez, Puerto Rico.

PO-063 Functional interrogation of immune escape in neoantigen-expressing pancreatic cancer identifies a critical role for the CD155/TIGIT axis. William Freed-Pastor[1], Laurens Lambert[1], Zackery Ely[1], Nimisha Pattada[1], Arjun Bhutkar[1], Alex Jaeger[1], George Eng[1], Kim Mercer[1], William Hwang[1], Tyler Jacks[1]. [1]MIT, Cambridge, MA.

PO-064 ONC212 stimulates cytotoxic T-cell killing, increases tumor-immune cell interactions, and promotes tumor regression in combination with TLY012 in a PDAC murine model. Kelsey E. Huntington[1], Anna Louie[1], Young Lee[1], Jared Mompoint[1], Isacco Ferrarini[2], Aakash Jhaveri[3], Varun V. Prabhu[4], Allen Melemed[4], Seulki Lee[5], Wafik S El-Deiry[1]. [1]Brown University, Providence, RI, [2]University of Verona, Verona, Italy, [3]Sidney Kimmel Medical College, Philadelphia, PA, [4]Chimerix, Durham, NC, [5]D&D Pharmatech, Gaithersburg, MD.

PO-065 SIWA318H, an advanced glycation end product (AGE) targeting antibody, is efficacious in a humanized mouse xenograft model for pancreatic cancer. Ashley Jensen[1], Gabriela R. Rossi[2], Ruben Muñoz[1], Kimberly Brothers[1], Lewis Gruber[2], Misty Gruber[2], Haiyong Han[1]. [1]Translational Genomics Research Institute, Phoenix, AZ, [2]SIWA Therapeutics, Inc., Chicago, IL.

PO-066 High uptake, retention, and in vivo activity of L-Annamycin in pancreatic cancer models. Ya'an Kang, Rafal Zielinski, Roberto Cardenas Zuniga, Radjendirane Venugopal, Maria Poimenidou, Magdalena Remiszewski, Shaohua Peng, Edd Felix, Krzysztof Grela, Stanislaw Skora, Van N. Nguyen, Izabela Fokt, Waldemar Priebe. UT MD Anderson Cancer Center, Houston, TX.

PO-067 A multi-omics study in patient-derived organoids reveals MNX1-HNF1B axis to be indispensable for intraductal mucinous papillary neoplasm lineages. Hiroyuki Kato[1], Keisuke Tateishi[1], Keisuke Yamamoto[1], Dousuke Iwadate[1], Hiroaki Fujiwara[2], Takuma Nakatsuka[1], Koji Miyabayashi[1], Yotaro Kudo[1], Ijichi Hideaki[1], Kazuhiko Koike[3], Mitsuhiro Fujishiro[1]. [1]Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, [2]Division of Gastroenterology, The Institute for Adult Diseases, Asahi Life Foundation, Tokyo, Japan, [3]Department of Gastroenterology, Kanto Central Hospital, Tokyo, Japan.

PO-068 Cholesterol auxotrophy promotes the expansion of centroacinar cells giving rise to the basal subtype of pancreatic adenocarcinoma. Michael Kotliar[1], Aizhan Surumbayeva[2], Linara Gabitova[2], Suraj Peri[3], Diana Restifo[2], Kathy Q. Cai[4], Artem Barski[5], Igor Astsaturov[2]. [1]Cincinnati Children's Hospital Medical Center, Cincinnati, OH, [2]The Marvin & Concetta Greenberg Pancreatic Cancer Institute, Fox Chase Cancer Center, Philadelphia, PA, [3]Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, PA, [4]Histopathology Facility, Fox Chase Cancer Center, Philadelphia, PA, [5]Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, OH.

PO-069 Modeling the tumor microenvironment using tissue engineering technologies. Rodrigo Curvello[1], Verena Kast[2], Daniela Loessner[1]. [1]Monash University, Clayton, Australia, [2]Max Bergmann Center of Biomaterials Dresden, Dresden, Germany.

PO-070 Longitudinal precision oncology platform to identify chemotherapy-induced vulnerabilities in pancreatic cancer. Katja Peschke[1], Hannah Jakubowski[1], Arlett Schäfer[1], Carlo Maurer[1], Sebastian Lange[1], Felix Orben[1], Raquel Bernad[1], Felix Harder[1], Matthias Eiber[1], Rupert Öllinger[1], Melissa Schlitter[1], Wilko Weichert[1], Veit Phillip[1], Christoph Schlag[1], Roland Schmid[1], Rickmer Braren[1], Bo Kong[2], Ekin Demir[1], Helmut Friess[1], Roland Rad[1], Dieter Saur[1], Günter Schneider[1], Maximilian Reichert[1]. [1]Technical University of Munich, Klinikum rechts der Isar, Munich, Germany, [2]University of Ulm, Ulm, Germany.

PO-072 Inhibiting vasoactive intestinal peptide receptor signaling elicits T cell dependent anti-tumor response of pancreatic ductal adenocarcinoma to immune checkpoint therapy. Sruthi Ravindranathan[1], Passang Tenzin[1], Jian Ming Li[1], Rohan

Dhamsania[1], Michael Ware[1], Mohammad Zaidi[1], Shuhua Wang[1], Jingru Zhu[1], Maria Cardenas[1], Yuan Liu[1], Gaurav Joshi[1], Sanjeev Gumber[1], Brian Robinson[1], Anish Sen-Majumdar[2], Shanmuganathan Chandrakasan[1], Haydn Kissick[1], Alan Frey[2], Susan Thomas[3], Bassel El-Rayes[1], Gregory Lesinski[1], Edmund K. Waller[1]. [1]Emory University, Atlanta, GA, [2]Cambium Oncology, Atlanta, [3]Georgia Institute of Technology, Atlanta.

PO-073 Inactivation of Notch4 attenuated pancreatic tumorigenesis in mice. Kiyoshi Saeki[1], Wanglong Qiu[1], Richard Friedman[1], Carrie Shawber[1], Jan Kitajewski[2], Jianhua Hu[1], Gloria H. Su[1]. [1]Columbia University Irving Medical Center, New York, NY, [2]University of Illinois Chicago, Chicago, IL.

PO-074 Identification of C-MET receptor as a therapeutic target in patient-specific tumoroid models of metastatic pancreatic adenocarcinoma allows identification of a new mode of action for its inhibitors. Liam Deems, Maria Ivanova, Cheryl Murphy, Amit Shahar, David Deems, Dmitry Shvartsman. Cellaria Inc., Wakefield, MA.

PO-075 The elucidation of the role of Prrx1 for acinar to ductal metaplasia in response to acute injury of pancreas in the novel mouse models. Kensuke Suzuki[1], Alina Li[1], Jason R. Pitarresi[1], Anna M. Chiarella[1], Gizem Efe[1], Kensuke Sugiura[1], Rohit Chandwani[2], Anil K. Rustgi[1]. [1]Herbert Irving Comprehensive Cancer Center, Division of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, [2]Department of Surgery, Weill-Cornell Medical School, New York, NY.

PO-076 Murine adapted FOLFIRINOX for standard-of-care in KPC mice. Martin C. Whittle, Aditi Palkar, Rachael Fasnacht, James Yan, Borith Kheng, Kianna Sinfuego, Shelley Thorsen, Sunil R. Hingorani. Fred Hutchinson Cancer Research Center, Seattle, WA.

PO-077 Establishment of a novel living biobank of patient-derived pancreatic cancer organoids with genomic and drug response characterization. Irene Y. Xie[1], Laura Tamblyn[2], Karen Ng[2], Eugenia Flores-Figueroa[2], Julie M. Wilson[3], Gun Ho Jang[3], Amy X. Zhang[3], Stephanie Ramotar[2], Anna Dodd[2], Nikolina Radulovich[2], Jennifer J. Knox[2], Grainne M. O'Kane[2], Steven Gallinger[2], Faiyaz Notta[2]. [1]University of Toronto, Toronto, ON, Canada, [2]University Health Network, Toronto, ON, Canada, [3]Ontario Institute of Cancer Research, Toronto, ON, Canada.

PO-079 Proteomic profiling reveals subtype specific kinase expression in pancreatic cancer. Yi Xu, Michael East, Ashley Morrison, Gabriela Herrera, Laura Peng, Gary Johnson, Jen Jen Yeh. UNC Chapel Hill, Chapel Hill, NC.

PO-080 Patient-derived organoids and cancer associated fibroblasts as a co-culture model to explore cell type interactions in pancreatic cancer. Jacquelyn W. Zimmerman, Genevieve Stein-O'Brien, Richard A. Burkhart, Elana J. Fertig, Elizabeth M. Jaffee. Johns

Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

Signaling

PO-081 Studying MYC's contribution to replication stress at the nuclear pore. Gabriel M. Cohn, Colin J. Daniel, Daniel F. Liefwalker, Rosalie C. Sears. Oregon Health & Science University, Portland, OR.

PO-082 Delineating the molecular basis of early dissemination of pancreatic cancer. Taelor Ekstrom[1], Dmytro Grygoryev[1], Terry Morgan[2], Kenneth S Zaret[3], Jungsun Kim[4]. [1]Cancer Early Detection Advanced Research Center, Oregon Health & Science University, Portland, OR, [2]Cancer Early Detection Advanced Research Center, Department of Pathology, Knight Cancer Institute (Cancer Biology Research Program), Oregon Health & Science University School of Medicine, Portland, OR, [3]Institute for Regenerative Medicine, Department of Cell and Developmental Biology, Abramson Cancer Center (Tumor Biology Program), University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, [4]Cancer Early Detection Advanced Research Center, Department of Molecular and Medical Genetics, Knight Cancer Institute (Cancer Biology Research Program), Oregon Health & Science University School of Medicine, Portland, OR.

PO-084 The role of p53 in the development of pancreatic ductal adenocarcinoma. Kathryn J. Hanson, Brittany M. Flowers, Nicholas Hughes, Hannes Vogel, Le Cong, Laura D. Attardi. Stanford University, Stanford, CA.

PO-086 Exploring therapeutic strategies against Pancreatic Ductal Adenocarcinoma (PDAC). Vasiliki Liaki. Spanish National Cancer Research Center (CNIO), Madrid, Spain.

PO-088 Classification based on efficiency of mRNA translation reveals a metabolically-dependent subtype of pancreatic cancer. Sauyeun Shin[1], Remy Nicolle[2], Mehdi Liauzun[1], Jacobo Solorzano[1], Alexia Brunel[1], Christine Jean[1], Remi Samain[1], Jerôme Raffenne[1], Cindy Neuzillet[3], Carine Joffre[4], Stephane Rocci[5], Juan Iovanna[6], Nelson Dusetti[6], Ola Larsson[7], Stephane Pyronnet[1], Corinne Bousquet[1], Yvan Martineau[1]. [1]CRCT, Inserm U1037, Toulouse, France, [2]CIT, Ligue Nationale Contre Le Cancer, Paris, France, [3]Medical Oncology Department, Curie Institute, Saint Cloud, France, [4]CRCT Inserm U1037, Toulouse, France, [5]C3M, Inserm U1065, Nice, France, [6]CRCM, Inserm, Marseille, France, [7]Karolinska Institutet, Stockholm, Sweden.

PO-089 Identification of a LAMC2-regulated network featuring targetable effectors for dual therapies in pancreatic cancer. Shruthi Narayanan[1], Oihane Erice[2], Iker Feliu[2], Caterina Vicentini[3], Rodrigo Entrialgo-Cadierno[2], Karmele Valencia[2], Elisabet Guruceaga[4], Purvesh Khatri[5], Vicenzo Corbo[3], Silvestre Vicent Cambra[6], Mariano Ponz-Sarvise[1]. [1]Clinica Universidad de Navarra, Medical Oncology Department, Pamplona, Spain, [2]University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain, [3]Department of Diagnostics and Public Health, University of Verona, Verona, Italy, [4]University

of Navarra, Center for Applied Medical Research, Computational Biology Program, Pamplona, Spain, [5]Stanford University, Stanford, CA, [6]University of Navarra, Center for Applied Medical Research, Program in Solid Tumors and Department of Pathology, Anatomy and Physiology; IdiSNA, Navarra Institute for Health Research; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain, Pamplona, Spain.

PO-090 TGF-β induced EMT gene expression is associated with promoter demethylation in pancreatic cancer. Manjul Rana[1], Abul Elahi[1], Abidemi O. Ajidahun[1], Rita G. Kansal[1], Anders E. Berglund[2], David Shibata[1], Evan S. Glazer[1]. [1]UTHSC, Memphis, TN, [2]Moffitt Cancer Center, Tampa, FL.

PO-091 Histamine receptor 1 (HRH1): A potentially novel G protein-coupled receptor (GPCR) therapeutic target in pancreatic adenocarcinoma (PDAC) cells and tumors. Cristina Salmeron, Krishna Sriram, Mehrak Javadi-Paydar, Paul A. Insel. [1]UCSD, La Jolla, CA.

PO-092 Influence of the IL-13-receptor alpha 1 chain on the malignant phenotype of pancreatic cancer cells. Jingwei Shi, Marko Kornmann, Benno Traub. University of Ulm, Ulm, Germany.

PO-093 JNK2 suppresses the growth and invasion of pancreatic cancer and is opposed by JNK1. Jingwei Shi, Xiaodong Tian, Marko Kornmann, Benno Traub. University of Ulm, Ulm, Germany.

PO-094 Gα13 loss in KPC mouse model promotes well-differentiated pancreatic tumors that are susceptible to mTOR inhibition. Mario A. Shields, Christina Spaulding, Mahmoud G. Khalafalla, Thao N. D. Pham, Hidayatullah G. Munshi. Northwestern University, Chicago, IL.

Tumor Microenvironment

PO-095 A cancer cell-intrinsic GOT2-PPARδ axis suppresses antitumor immunity. Jaime Abrego[1], Hannah Sanford-Crane[1], Chet Oon[1], Xu Xiao[2], Courtney Betts[1], Duanchen Sun[3], Shanthi Nagarajan[4], Zheng Xia[3], Lisa Coussens[1], Peter Tontonoz[5], Mara Sherman[1]. [1]Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR, [2]Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, [3]Computational Biology Program, Oregon Health & Science University, Portland, OR, [4]Medicinal Chemistry Core, Oregon Health & Science University, Portland, OR, [5]Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.

PO-096 The synaptic protein Netrin G1 ligand (NGL-1) modulates tumorigenesis and immunosuppression in pancreatic cancer. Debora Barbosa Vendramini Costa[1], Ralph Francescone[1], Janusz Franco-Barraza[1], Tiffany Luong[1], Nina Steele[2], Benjamin Allen[2], Marina Pasca di Magliano[3], Charline Ogier[1], Igor Astsaturov[1], Kathy Q Cai[1], Andres J Klein-Szanto[1],

Huamin Wang[4], Kerry Campbell[1], Edna Cukierman[1]. [1]Fox Chase Cancer Center, Philadelphia, PA, [2]Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI, [3]Department of Surgery, University of Michigan, Ann Arbor, MI, [4]Department of Anatomical Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

PO-097 Addition of losartan to FOLFORINOX and chemoradiation reduces the expression of pro-invasive and immunosuppressive genes in locally-advanced pancreatic cancer. Yves Boucher[1], Jessica M. Posada[2], Sonu Subudhi[2], Ashwin S. Kumar[2], Ivy X. Chen[2], Mei R. Ng[2], Mari Mino-Kenudson[3], Nilesh Talele[2], Dan G. Duda[2], Dai Fukumura[3], Janet E. Murphy[3], Jeffrey W. Clark[3], David P. Ryan[3], Carlos Fernandez-Del Castillo[3], Theodore S. Hong[3], Rakesh K. Jain[3]. [1]Massachusetts General Hospital and Harvard Medical School, Boston, MA, [2]Massachusetts General Hospital, Boston, MA, [3]Massachusetts General Hospital, Harvard Medical School, Boston, MA.

PO-098 Longitudinal profiling of pancreatic cancer patients identifies interleukin-8 as a mediator of myeloid-epithelial crosstalk. Eileen S. Carpenter[1], Samantha Kemp[2], Padma Kadiyala[1], Nina Steele[1], Ahmed Elhossiny[1], Stephanie The[1], Valerie Gunchick[1], Rémy Nicolle[3], Michelle Anderson[1], Wenting Du[1], Carlos Espinoza[1], Richard Kwon[1], Erik-Jan Wamsteker[1], Anoop Prabhu[1], Allison Schulman[1], Vaibhav Sahai[1], Timothy Frankel[1], Filip Bednar[1], Marina Pasca di Magliano[1]. [1]University of Michigan, Ann Arbor, MI, [2]University of Pennsylvania, Philadelphia, PA, [3]Tumour Identity Card Program (CIT), French League Against Cancer, Paris, France.

PO-100 Lorazepam promotes desmoplasia and ischemic necrosis in murine pancreatic ductal adenocarcinoma. Abigail C. Cornwell, Abdulrahman A. Alahmari, Arwen A. Tisdale, Kathryn Maraszek, Swati Venkat, Michael E. Feigin. Roswell Park Comprehensive Cancer Center, Buffalo, NY.

PO-101 Characterization of longitudinally collected fine needle aspiration biopsies of pancreatic ductal adenocarcinoma upon endoscopic ultrasound guided radiofrequency ablation. Krisha Desai[1], Patrick Varun Lawrence[1], Christopher Wadsworth[2], Nagina Mangal[2], Nagy Habib[2], Anguraj Sadanandam[1], Mikael Sodergren[2]. [1]Institute of Cancer Research, London, United Kingdom, [2]Imperial College, London, United Kingdom.

PO-102 Fibroblast-derived interleukin-33 promotes pancreatic ductal adenocarcinoma as a result of tumor cell KRAS^{G12D}. Katelyn Donahue, Wenting Du, Carlos Espinoza, Eileen Carpenter, Kristee Brown, Nina Steele, Marina Pasca di Magliano. University of Michigan, Ann Arbor, MI.

PO-103 Cellular origin influences immune microenvironment in a pancreatic cancer mouse model with loss of Pten and activation of Kras. Yan Dou[1], Wesley Hunt[1], Justin Chhuor[1], Farnaz Taghizadeh[1], Atefeh Samani[1], Karnjit Sarai[1], Claire Dubois[2], David F. Schaeffer[1], Maike Sander[2], Janel L. Kopp[1]. [1]University of British Columbia, Vancouver, BC, Canada, [2]University of California-San Diego, La Jolla, CA.

PO-104 Activation of WNT signaling in CD4$^+$ T cells promotes immune suppression in pancreatic cancer. Wenting Du, Rosa E. Menjivar, Katelyn Donahue, Ashley Velez-Delgado, Marina Pasca di Magliano. University of Michigan, Ann Arbor, MI.

PO-105 Overcoming stromal barriers in PDA with a novel polymeric Toll-like receptor agonist. Christopher C. DuFort[1], Ciana L. Lopez[2], Martin C. Whittle[1], Vladimir Vlaskin[2], Aditi Vadodkar[1], Selvi Srinivasan[2], Patrick S. Stayton[2], Sunil R. Hingorani[1]. [1]Fred Hutchinson Cancer Research Center, Seattle, WA, [2]University of Washington, Seattle, WA.

PO-106 The extrinsic and modulatory effects of CSF-1/CSF-1R signaling in generating an immunosuppressive pancreatic cancer tumor microenvironment and promoting metastasis. Gizem Efe[1], Kensuke Suzuki[1], Jason R. Pitarresi[2], Anna M. Chiarella[1], Alina L. Li[1], Anil K. Rustgi[1]. [1]Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, [2]Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.

PO-107 Fibroblast differentiation trajectories elicit regional tissue states in pancreatic cancer Barbara T. Grünwald[1], Curtis McCloskey[1], Antoine Devisme[2], Foram Vyas[1], Geoffroy Andrieux[2], Kazeera Aliar[1], Faiyaz Notta[3], Grainne O'Kane[1], Julie Wilson[3], Jennifer Knox[1], Sandra Fischer[4], Thomas Kislinger[1], Melanie Boerries[2], Steven Gallinger[3], Rama Khokha[5]. [1]Princess Margaret Cancer Centre, Toronto, ON, Canada, [2]University of Freiburg, Freiburg, Germany, [3]Ontario Institute for Cancer Research, Toronto, ON, Canada, [4]University Health Network, Toronto, ON, Canada, [5]Princess Margaret Cancer Centre, Toronto, Canada.

PO-108 Evaluation of antitumor activity of modified-gemcitabine solid-lipid nanoparticle in pancreatic pdx models. Edward Agyare[1], Taylor Smith[2], Andriana Inkoom[1], Bo Han[3], Jose Trevino[4], Nkafu Bechem Ndemazie[1]. [1]College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, [2]Food and Drug Administration, Silver Spring, MD, [3]Keck School of Medicine, University of Southern California, Los Angeles, CA, [4]Department of Surgery, College of Medicine, Virginia Commonwealth University, Richmond, VA.

PO-110 Targeting Cathepsin B in the pancreatic stellate cells stimulates CD8+ T cell dependent anti-tumor immune response. Bharti Garg, Tejeshwar Jain, Utpreksha Vaish, Vikas Dudeja. University of Alabama at Birmingham, birmingham, AL.

PO-111 A Human Single-cell RNA Sequencing Atlas of Pancreatic Ductal Adenocarcinoma Enables Harmonized Cell Type Calling and Comprehensive Analyses of Potential Intercellular Signaling. Benedict Kinny-Köster[1], Melissa R. Lyman[2], Dimitrios N. Sidiropoulos[2], Melanie Loth[2], Alexandra B. Puscek[2], Laura D. Wood[3], Jin He[1], Jun Yu[1], Richard A. Burkhart[1], Elizabeth M. Jaffee[2], Jacquelyn W. Zimmerman[2], Elana J. Fertig[2]. [1]Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, [2]Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, [3]Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD.

PO-112 Stromal reprogramming by FAK inhibition overcomes radiation resistance to

allow for immune priming and response to checkpoint blockade. Varintra E. Lander, Jad I. Belle, Brett L. Knolhoff, John M. Herndon, Cedric Mpoy, Buck E. Rogers, Julie K. Schwarz, David G. DeNardo. Washington University in St. Louis, St. Louis, MO.

PO-113 The prolyl isomerase PIN1 plays a critical role in fibroblast differentiation states to support pancreatic cancer. Ellen M. Langer[1], Isabel A English[1], Vidhi Shah[1], Kevin MacPherson[1], Kayleigh M. Kresse[1], Brittany L. Allen-Petersen[2], Colin J. Daniel[1], Mara H. Sherman[1], Andrew Adey[1], Rosalie C. Sears[1]. [1]Oregon Health & Science University, Portland, OR, [2]Purdue University, West Lafayette, IN.

PO-114 STAT3 in cancer-associated fibroblasts promotes an immunosuppressive tumor microenvironment. Julia E. Lefler, Michael Ostrowski, Catherine MarElia-Bennett. Medical University of South Carolina (MUSC), Charleston, SC.

PO-115 Effects of mesothelin exert on tumor microenvironment in pancreatic ductal adenocarcinoma. Dongliang Liu[1], Ethan Poteet, Zhengdong Liang, Emily Laplante, Lisa Brubaker, Sadhna Dhingra, Aleksandar Milosavljevic, Changyi Chen, Qizhi Cathy Yao. Baylor College of Medicine, Houston, TX.

PO-116 Deletion of *Arginase 1* in myeloid cells alters the pancreatic cancer microenvironment. Rosa E. Menjivar[1], Zeribe Nwosu[1], Wenting Du[1], Katelyn Donahue[1], Carlos Espinoza[1], Ashley Velez-Delgado[1], Kristee Brown[1], Wei Yan[1], Christopher Halbrook[2], Yaqing Zhang[1], Costas Lyssiotis[1], Marina Pasca di Magliano[1]. [1]University of Michigan, Ann Arbor, MI, [2]University of California Irvine, Irvine, CA.

PO-117 The role of Hippo signaling in stromal-epithelial interactions in acinar-to-ductal metaplasia and pancreatic cancer initiation. Julia Messina-Pacheco[1], Yasser Riazalhosseini[2], Zu-hua Gao[1], Alex Gregorieff[1]. [1]Department of Pathology, McGill University and the Research Institute of McGill University Health Centre, Montreal, QC, Canada, [2]Department of Human Genetics, McGill University and the McGill University and Genome Quebec Innovation Centre, Montreal, QC, Canada.

PO-118 The tumor immune microenvironment is decisive in the survival of pancreatic ductal adenocarcinoma. Hosein M. Aziz, Lawlaw Saida, Willem de Koning, Andrew Stubbs, Yunlei Li, Casper H. J. van Eijck, Dana A. M. Mustafa. Erasmus University Medical Center, Rotterdam, Netherlands.

PO-119 DFMO mediated improvement in survival of an orthotopic model of pancreatic cancer is associated with modulating immune suppression in the tumor microenvironment. Sai Preethi Nakkina[1], Sarah B. Gitto[2], Veethika Pandey[2], Jordan M. Beardsley[1], Michael W. Rohr[1], Jignesh G. Parikh[3], Otto Phanstiel[4], Deborah A. Altomare[1]. [1]University of Central Florida, Orlando, FL, [2]University of Pennsylvania, Philadelphia, PA, [3]Orlando VA Medical Center, Orlando, FL, [4]College of Medicine, University of Central Florida, Orlando, FL.

PO-120 Differential expression of polyamine pathways in human pancreatic tumor progression and effects of polyamine blockade therapy on the *in vivo* pancreatic tumor

microenvironment. Sai Preethi Nakkina[1], Sarah B. Gitto[2], Veethika Pandey[2], Jignesh G. Parikh[3], Dirk Geerts[4], Kenneth P. Olive[5], Otto Phanstiel[6], Deborah A. Altomare[1], Carlo Maurer[7]. [1]University of Central Florida, Orlando, FL, [2]University of Pennsylvania, Philadelphia, PA, [3]Orlando VA Medical Center, Orlando, FL, [4]University of Amsterdam, Amsterdam, Netherlands, [5]Columbia University Medical Center, Ney York, NY, [6]College of Medicine, Orlando, FL, [7]Klinikum rechts der Isar der TU München, Munchen, Germany.

PO-121 Investigating the role of human cancer-associated fibroblasts in pancreatic cancer invasion using patient-derived PDAC organoids. Bernat Navarro-Serer, Kenna Sherman, Laura D. Wood. Johns Hopkins University School of Medicine, Baltimore, MD.

PO-122 Combined CDK and BET inhibition reprograms the tumor and stromal compartments to enhance anti-tumor immunity in immunologically-cold CDKN2A-deficient pancreatic cancer. Brian M. Olson, Alison J. Thomas, Michael B. Ware, Gregory B. Lesinski. Emory University, Atlanta, GA.

PO-123 Development of a 3D Biomimetic Metastatic Liver Niche Model for Pancreatic Cancer. Mahsa Pahlavan[1], Weikun Xiao[2], Flora Eun[2], Chang-Il Hwang[3], Reginald Hill[2]. [1]Department of Biomedical Engineering, University of Southern California, Los Angeles, CA, [2]Lawrence J. Ellison Institute for Transformative Medicine of USC, University of Southern California, Los Angeles, CA, [3]Department of Microbiology and Molecular Genetics, College of Biological Sciences, University of California Davis, Davis, CA.

PO-124 EZH2 blockade overcomes suppression of the proinflammatory senescence-associated secretory phenotype in the pancreas and drives NK cell-mediated pancreatic tumor responses. Loretah Chibaya[1], Yvette Lopez-Diaz[1], Haibo Liu[1], Katherine C Murphy[1], John P. Morris IV[2], Yu-jui Ho[2], Janelle Simon[2], Wei Luan[2], Amanda Kulick[2], Lakhena Leang[1], Elisa de Stanchina[2], Lihua J. Zhu[1], Scott W. Lowe[2], Marcus Ruscetti[1]. [1]University of Massachusetts Medical School, Worcester, MA, [2]Memorial Sloan Kettering Cancer Center, New York, NY.

PO-125 The role of KDM6A in pancreatic cancer immune microenvironment. Lin Jin, Jing Yang, Zhujun Yi, Hong S Kim, Feng Tian, Jiaqi Shi. University of Michigan, Ann Arbor, MI.

PO-126 Loss of HIF1A decreases resistance to radiation and invasiveness in pancreatic ductal adenocarcinoma. Kevin J. Tu[1], Sanjit K. Roy[1], Binny Bhandary[2], Amit Sawant[1], Hem D. Shukla[1]. [1]University of Maryland School of Medicine, Baltimore, MD, [2]University of Maryland, Baltimore, Baltimore, MD.

PO-127 A uPA/uPAR axis in both the tumor cell and stromal compartment drives PDAC disease progression. Yi Yang, Sara R. Abrahams, Aditi Kothari, Harshi Matada, Keely Davey, Alisa S. Wolberg, Matthew J. Flick. University of North Carolina, Chapel Hill, Chapel Hill, NC.

PO-129 Targeting CCR1 reprograms tumor associated macrophages in pancreatic cancer. Yaqing Zhang, Kristee L. Brown, Wei Yan, Zeribe C. Nwosu, Eileen K. Carpenter, Katelyn L. Donahue, Ashley Velez-Delgado, Sion Yang, Marina Pasca di Magliano. University of Michigan, Ann Arbor, MI.

PO-130 Macropinocytosis at the nexus of crosstalk in the pancreatic tumor microenvironment. Yijuan Zhang[1], M. Victoria Recouvreux[1], Michael Jung[1], Koen Galencamp[1], Yunbo Li[2], Olga Zagnitko[1], David Scott[1], Andrew Lowy[2], Cosimo Commisso[1]. [1]Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, [2]University of California San Diego, La Jolla, CA.

PO-131 The role of liver endothelium on pancreatic cancer growth. Wei Zhang[1], Michel'le Wright[1], Moeez Rathore[1], Ali Vaziri-Gohar[1], Jordan Winter[2], Rui Wang[2]. [1]Case Western Reserve University, Cleveland, OH, [2]Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH.